Investors Buy High Volume of Call Options on Hims & Hers Health (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) saw some unusual options trading activity on Wednesday. Stock investors bought 47,929 call options on the stock. This represents an increase of 59% compared to the typical daily volume of 30,093 call options.

Insider Activity at Hims & Hers Health

In other news, Director Christiane Pendarvis sold 7,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $15.15, for a total value of $106,050.00. Following the completion of the sale, the director now owns 23,917 shares of the company’s stock, valued at approximately $362,342.55. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total value of $2,750,209.28. Following the completion of the transaction, the chief executive officer now owns 33,502 shares of the company’s stock, valued at approximately $487,789.12. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Christiane Pendarvis sold 7,000 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $15.15, for a total transaction of $106,050.00. Following the completion of the sale, the director now owns 23,917 shares in the company, valued at $362,342.55. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 650,659 shares of company stock worth $11,712,198. Insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Several institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Hims & Hers Health by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock valued at $221,379,000 after purchasing an additional 136,907 shares during the last quarter. Renaissance Technologies LLC raised its position in Hims & Hers Health by 113.1% during the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after buying an additional 3,205,108 shares during the last quarter. Farallon Capital Management LLC raised its position in Hims & Hers Health by 3,890.5% during the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after buying an additional 1,634,000 shares during the last quarter. Bank of New York Mellon Corp raised its position in Hims & Hers Health by 67.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company’s stock worth $13,701,000 after buying an additional 273,473 shares during the last quarter. Finally, M&G Plc purchased a new position in Hims & Hers Health during the 1st quarter worth $8,232,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

HIMS opened at $23.44 on Thursday. The business’s 50-day simple moving average is $18.22 and its 200-day simple moving average is $18.26. The stock has a market capitalization of $5.03 billion, a P/E ratio of 53.27 and a beta of 1.06. Hims & Hers Health has a one year low of $6.58 and a one year high of $25.74.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 11.67% and a net margin of 8.19%. The business had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same period in the prior year, the company earned ($0.04) earnings per share. The company’s revenue was up 77.1% compared to the same quarter last year. On average, equities research analysts forecast that Hims & Hers Health will post 0.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on HIMS. Truist Financial raised their price target on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, July 18th. TD Cowen raised their price target on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Bank of America raised their price target on shares of Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Needham & Company LLC assumed coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price on the stock. Finally, Imperial Capital downgraded shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Eight equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.